Verastem, Inc. (NASDAQ:VSTM – Get Free Report) has received a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $16.83.
VSTM has been the subject of a number of analyst reports. Weiss Ratings lowered Verastem from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 15th. Wall Street Zen lowered Verastem from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Mizuho boosted their target price on shares of Verastem from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Friday, October 16th. Jefferies Financial Group reaffirmed a “buy” rating and set a $13.00 target price (up from $11.00) on shares of Verastem in a report on Wednesday, October 14th. Finally, Royal Bank Of Canada dropped their price objective on Verastem from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, November 6th.
View Our Latest Analysis on Verastem
Verastem Trading Down 3.1%
NASDAQ:VSTM traded down $0.26 during mid-day trading on Tuesday, hitting $8.18. 1,721,447 shares of the stock traded hands, compared to its average volume of 3,510,027. The company has a quick ratio of 2.22, a current ratio of 1.93 and a debt-to-equity ratio of 11.19. Verastem has a 52 week low of $3.43 and a 52 week high of $10.82. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -3.99 and a beta of 0.45. The firm’s 50 day moving average is $8.49 and its two-hundred day moving average is $6.30.
Verastem (NASDAQ:VSTM – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.27). The business had revenue of $24.01 million for the quarter, compared to analysts’ expectations of $26.57 million. Verastem had a negative net margin of 178.38% and a negative return on equity of 359.49%. On average, equities research analysts predict that Verastem will post -1.72 earnings per share for the current year.
Insider Buying and Selling
In related news, CEO Dan Paterson sold 44,121 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $8.00, for a total value of $352,968.00. Following the completion of the transaction, the chief executive officer directly owned 652,712 shares of the company’s stock, valued at approximately $5,221,696. This represents a 6.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 48,041 shares of company stock valued at $386,390. 1.94% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Aries Wealth Management lifted its stake in shares of Verastem by 6.5% during the third quarter. Aries Wealth Management now owns 32,833 shares of the biopharmaceutical company’s stock worth $264,000 after purchasing an additional 2,000 shares in the last quarter. FORA Capital LLC acquired a new stake in shares of Verastem in the third quarter valued at about $88,000. Simplicity Wealth LLC acquired a new stake in shares of Verastem in the third quarter valued at about $89,000. Royal Bank of Canada raised its holdings in shares of Verastem by 15.3% during the 1st quarter. Royal Bank of Canada now owns 110,729 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 14,683 shares during the period. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of Verastem during the 3rd quarter valued at about $122,000. 88.37% of the stock is currently owned by hedge funds and other institutional investors.
Verastem Company Profile
Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway. The company’s product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.
See Also
- Five stocks we like better than Verastem
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.
